Literature DB >> 9416807

1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis.

C A Davie1, G J Barker, A J Thompson, P S Tofts, W I McDonald, D H Miller.   

Abstract

OBJECTIVES: To test the hypothesis that irrecoverable neurological deficit in multiple sclerosis is associated with axonal loss.
METHODS: 1H magnetic resonance spectroscopy (MRS) was carried out in a group of patients with clinically definite multiple sclerosis (n=31). Using this technique, the apparent concentration of NA ([NA] the sum of N-acetyl aspartate (NAA), a neuronal marker, and N-acetylaspartylglutamate has been compared in four groups of patients with multiple sclerosis classified as relapsing-remitting, secondary progressive, primary progressive, benign, and a control group.
RESULTS: In the patients with relapsing-remitting disease (n=9) there was a highly significant reduction of apparent NA (median 8.73 mM, range 6.86 mM-10.74 mM, P=0.0008) from an area of high signal compared with the control group (median 11.97 mM, range 10.55 mM-14.5 mM). In the patients with secondary progressive disease (n=10), there was again a highly significant reduction of apparent NA (median 7.82 mM, range 3.5 mM-10.3 mM, P=0.0003) from an area of high signal compared with the control group. In the patients with primary progressive disease (n=6) there was once again a highly significant reduction of apparent NA (median 8.83 mM, range 6.95 mM-9.89 mM, P<0.002) from an area of high signal compared with the control group. In the patients with benign disease, however, there was no significant difference in the apparent NA (median 10.5 mM, range 8.53 mM-12.8 mM, P>0.05) from an area of high signal compared with the control group. In the patients with benign disease (n=5) there was also no significant difference in the apparent NA (median 10.74 mM, range 8.58 mM-13.4 mM, P>0.3) from an area of normal appearing white matter compared with the control group. In the patients with primary progressive disease, however, there was a significant reduction of apparent NA from an area of normal appearing white matter (median 8.78 mM, range 8.7 mM-12.38 mM, P< 0.025) compared with the control group. There was a significant inverse correlation between [NA] from lesions in the patients with multiple sclerosis and disability as measured on the Kurtzke expanded disability scale score (r= -0.364, 0.05>P>0.02).
CONCLUSION: These findings support the hypothesis that axonal loss is important in the development of disability in multiple sclerosis. They also provide evidence for axonal loss in normal appearing white matter in patients with primary progressive disease.

Entities:  

Mesh:

Year:  1997        PMID: 9416807      PMCID: PMC2169838          DOI: 10.1136/jnnp.63.6.736

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  33 in total

1.  1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders.

Authors:  M S van der Knaap; J van der Grond; P R Luyten; J A den Hollander; J J Nauta; J Valk
Journal:  Ann Neurol       Date:  1992-02       Impact factor: 10.422

2.  A clinical and laboratory study of benign multiple sclerosis.

Authors:  A J Thompson; M Hutchinson; J Brazil; C Feighery; E A Martin
Journal:  Q J Med       Date:  1986-01

Review 3.  Atypical and clinically silent multiple sclerosis: a report of 12 cases discovered unexpectedly at necropsy.

Authors:  J G Phadke; P V Best
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-05       Impact factor: 10.154

Review 4.  N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain.

Authors:  D L Birken; W H Oldendorf
Journal:  Neurosci Biobehav Rev       Date:  1989       Impact factor: 8.989

5.  Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques.

Authors:  D L Arnold; P M Matthews; G S Francis; J O'Connor; J P Antel
Journal:  Ann Neurol       Date:  1992-03       Impact factor: 10.422

6.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease.

Authors:  D L Arnold; P M Matthews; G Francis; J Antel
Journal:  Magn Reson Med       Date:  1990-04       Impact factor: 4.668

7.  Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity.

Authors:  D Kidd; A J Thompson; B E Kendall; D H Miller; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

8.  Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss.

Authors:  C A Davie; G J Barker; S Webb; P S Tofts; A J Thompson; A E Harding; W I McDonald; D H Miller
Journal:  Brain       Date:  1995-12       Impact factor: 13.501

9.  Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study.

Authors:  P Gideon; O Henriksen; B Sperling; P Christiansen; T S Olsen; H S Jørgensen; P Arlien-Søborg
Journal:  Stroke       Date:  1992-11       Impact factor: 7.914

10.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D Wicks; D G MacManus; B E Kendall; D P Kingsley; W I McDonald
Journal:  Ann Neurol       Date:  1991-01       Impact factor: 10.422

View more
  43 in total

1.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

2.  Analysis of normal-appearing white matter in multiple sclerosis: comparison of diffusion tensor MR imaging and magnetization transfer imaging.

Authors:  A C Guo; V L Jewells; J M Provenzale
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

3.  Multiple sclerosis normal-appearing white matter: pathology-imaging correlations.

Authors:  Natalia M Moll; Anna M Rietsch; Smitha Thomas; Amy J Ransohoff; Jar-Chi Lee; Robert Fox; Ansi Chang; Richard M Ransohoff; Elizabeth Fisher
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

Review 4.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

Review 5.  The application of NMR-based metabonomics in neurological disorders.

Authors:  Elaine Holmes; Tsz M Tsang; Sarah J Tabrizi
Journal:  NeuroRx       Date:  2006-07

Review 6.  The role of advanced magnetic resonance imaging techniques in primary progressive MS.

Authors:  Maria A Rocca; Martina Absinta; Massimo Filippi
Journal:  J Neurol       Date:  2011-08-04       Impact factor: 4.849

7.  1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

Authors:  J Suhy; W D Rooney; D E Goodkin; A A Capizzano; B J Soher; A A Maudsley; E Waubant; P B Andersson; M W Weiner
Journal:  Mult Scler       Date:  2000-06       Impact factor: 6.312

Review 8.  White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis.

Authors:  Melissa Cambron; Miguel D'Haeseleer; Guy Laureys; Ralph Clinckers; Jan Debruyne; Jacques De Keyser
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-04       Impact factor: 6.200

9.  Determination of multiple sclerosis plaque size with diffusion-tensor MR Imaging: comparison study with healthy volunteers.

Authors:  Susan M Kealey; Youngjoo Kim; Wythe L Whiting; David J Madden; James M Provenzale
Journal:  Radiology       Date:  2005-08       Impact factor: 11.105

10.  The basal ganglia: a substrate for fatigue in multiple sclerosis.

Authors:  N Téllez; J Alonso; J Río; M Tintoré; C Nos; X Montalban; A Rovira
Journal:  Neuroradiology       Date:  2007-10-23       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.